TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Regeneus Ltd. ( (AU:CMB) ).
Cambium Bio Limited has signed a Memorandum of Understanding with Locus Cell Co., Ltd. for the global commercial production of the Active Biologic Ingredient for Elate Ocular®, excluding Europe and the Middle East. This strategic partnership is a significant step in Cambium’s commercialization strategy, leveraging Locus Cell’s FDA-compliant facility to meet global demand as the company progresses through Phase 3 trials.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing therapies for dry eye disease, with its lead product being Elate Ocular®.
Average Trading Volume: 21,539
Technical Sentiment Signal: Hold
Current Market Cap: A$11.88M
See more data about CMB stock on TipRanks’ Stock Analysis page.